Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder
Psychiatry and Clinical Psychopharmacology · 12.08.2026 · 36 (4) · 338-360
DOI: 10.65801/pcp.3463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychiatry and Clinical Psychopharmacology, online erschienen am 12.08.2026. Verfasst von Danyun Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Schlaf
Abstract (Originalsprache)
Background
Sleep disorders are common in postmenopausal women and may contribute to cognitive decline. We investigated whether plasma biomarkers differentiate cognitive impairment (CI) in this population.
Methods
In this cross-sectional exploratory study, we recruited 105 outpatients with insomnia disorder (79 women and 26 men) aged 45-60 years with insomnia symptoms (PSQI > 5, ISI > 7). Cognition was assessed using the Chinese Brief Cognitive Test (CBCT) and Auditory Verbal Learning Test. Postmenopausal women were classified as CI or non-CI based on CBCT criteria. Plasma glial fibrillary acidic protein (GFAP), neurofilament light chain, orexin A, total tau, and phosphorylated tau-181 (p-Tau) were measured using enzyme-linked immunosorbent assay. Associations with cognition and exploratory classification performance were examined using correlation and receiver operating characteristic analyses.
Results
Postmenopausal women exhibited higher anxiety and poorer cognitive performance despite comparable insomnia severity. Among them (non-CI n=42; CI n=37), the CI group had higher plasma GFAP (14.82 vs. 12.42 ng/mL, P = .004) and p-Tau (1,002.18 vs. 918.27 pg/mL, P = .034). Biomarkercognition correlations were weak. GFAP showed the highest apparent performance among individual biomarkers (area under the curve, AUC = 0.672). The clinical information-adjusted model incorporating orexin A, GFAP, and p-Tau showed the highest apparent AUC among biomarker combinations (AUC = 0.755), although internally validated performance was more modest.
Conclusions
Plasma GFAP and p-Tau, with potential incremental contribution from orexin A, may provide exploratory information for identifying cognitive vulnerability in postmenopausal women with insomnia disorder. These exploratory findings require validation in larger and independent cohorts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Gynecology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou 310006, China.
- Department of Psychiatry, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- School of Life Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
- Zhejiang Key Laboratory of Precision Psychiatry, Hangzhou, China.
ORCID-Profile: Danyun Wang, Bing Chen, Kangyu Jin, Shangping Cheng, Bin Qin, Yuting Tian, Jing Lu, Ketan Chu
Zitieren
APA
Wang, D., Chen, B., Jin, K., Cheng, S., Qin, B., Tian, Y., Lu, J., & Chu, K. (2026). Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder. Psychiatry and Clinical Psychopharmacology, 36(4), 338-360. https://doi.org/10.65801/pcp.3463
Vancouver
Wang D, Chen B, Jin K, Cheng S, Qin B, Tian Y, et al. Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder. Psychiatry and Clinical Psychopharmacology. 2026;36(4):338-360. doi:10.65801/pcp.3463
BibTeX
@article{Wang2026,
author = {Wang, Danyun and Chen, Bing and Jin, Kangyu and Cheng, Shangping and Qin, Bin and Tian, Yuting and Lu, Jing and Chu, Ketan},
title = {Plasma Biomarkers Differentiate Cognitive Impairment in Postmenopausal Women with Insomnia Disorder},
journal = {Psychiatry and Clinical Psychopharmacology},
year = {2026},
volume = {36},
number = {4},
pages = {338--360},
doi = {10.65801/pcp.3463}
}
EUVIMED